|
Sign In to gain access to subscriptions and/or personal tools.
|
A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
John Hornberger, MD, MS
The SPHERE Institute/Acumen, LLC, Burlingame, California, Department of Veterans Affairs, Palo Alto, California, Department of Medicine, Stanford University School of Medicine, Stanford, California, jhornberger{at}cedarecon.com
Mark Holodniy, MD, FACP
AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California, Division of Infectious Diseases & Geographic Medicine, Stanford University, Stanford, California, Veterans Health Administration, Public Health Strategic Health Care Group, Washington, DC
Katherine Robertus, MPH
The SPHERE Institute/Acumen, LLC, Burlingame, California
Michael Winnike, BA
The SPHERE Institute/Acumen, LLC, Burlingame, California
Erin Gibson, MA
The SPHERE Institute/Acumen, LLC, Burlingame, California
Eric Verhulst, BA
The SPHERE Institute/Acumen, LLC, Burlingame, California
Objectives . To determine whether gaps exist in published cost-utility analyses as measured by their coverage of topics addressed in current HIV guidelines from the Department of Health and Human Services (DHHS). Design. A systematic review of US-based cost-effectiveness analyses of HIV/AIDS prevention and management strategies, based on original, published research. Methods . Predefined criteria were used to identify all analyses pertaining to prevention and management of HIV/AIDS; information was collected on type of strategy, patient demographics, study perspective, quality of the study, effectiveness measures, costs, and cost-effectiveness ratios. Results . One hundred and six studies were identified; 62 described strategies for averting new HIV infections, and 44 dealt with managing persons who are HIV positive. The quality of studies was generally high, but gaps were found in all studies. Especially common were omissions in reporting data abstraction methodology and discussions of direction and magnitude of potential biases. Among the 22 most highly rated papers (score of 90 or higher), only 1 was cited in the guidelines, and 3 papers reported on interventions that were superseded by newer approaches. Using a $100,000 threshold, the guidelines usually endorsed interventions found to be cost-effective. Exceptions included recommending postexposure prophylaxis (PEP) for populations in which PEP is unlikely to be cost-effective and not recommending primary resistance testing in treatment-naive persons, although the intervention was reported to have a cost-effectiveness ratio of less than $50,000. Conclusions . Despite an abundant literature on the cost-utility of HIV/AIDS-targeted strategies, guidelines cite relatively few of these papers, and gaps exist regarding assessments of some strategies and special populations.
Key Words: Key words: HIV economics cost and cost analyses cost-utility public policy.
References
- Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253—8.[Abstract/Free Full Text]
- Weinstein MC, O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6:9—17.[Medline]
[Order article via Infotrieve]
- Neumann P. Evidence-based and value-based formulary guidelines. Health Aff. 2003;23:124—34.
- O'Brien BJ Academy of Managed Care Pharmacy Format: relevance, rigor, regulation, and realism. Value Health. 2003;6:501—2.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Fry RN, Avey SG, Sullivan SD The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard—a Foundation for Managed Care Pharmacy Task Force report. Value Health. 2003;6:505—21.[CrossRef]
- Garber A. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff. 2004;24:284—96.
- Blumstein JF The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. Soc Sci Med. 1997; 45:545—54.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tengs TO An evaluation of Oregon's Medicaid rationing algorithms. Health Econ. 1996;5:171—81.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tengs TO, Meyer G., Siegel JE, Pliskin JS, Graham JD, Weinstein MC Oregon's Medicaid ranking and cost-effectiveness: is there any relationship? Med Decis Making. 1996;16:99—107.[Abstract/Free Full Text]
- AuBuchon JP, Birkmeyer JD, Busch MP Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion. 1997;37:45—51.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bedimo AL, Pinkerton SD, Cohen DA, Gray B., Farley TA Condom distribution: a cost-utility analysis. Int J STD AIDS. 2002;13:384—92.[Abstract/Free Full Text]
- Busch MP, Dodd RY, Lackritz EM, AuBuchon JP, Birkmeyer JD, Petersen LR Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group. Transfusion. 1997;37:1003—11.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chavey WE, Cantor SB, Clover RD, Reinarz JA, Spann SJ Cost-effectiveness analysis of screening health care workers for HIV. J Fam Pract. 1994;38:249—57.[Web of Science][Medline]
[Order article via Infotrieve]
- Chen KT, Sell RL, Tuomala RE Cost-effectiveness of elective Cesarean delivery in human immunodeficiency virus-infected women. Obstet Gynecol. 2001;97:161—8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chesson HW, Greenberg JB, Hennessy M. The cost-effectiveness of the WINGS intervention: a program to prevent HIV and sexually transmitted diseases among high-risk urban women. BMC Infect Dis. 2002;2:24.[CrossRef]
- Coco A. The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med. 2005;3:391—9.[CrossRef]
- Doyle NM, Levison JE, Gardner MO Rapid HIV versus enzyme-linked immunosorbent assay screening in a low-risk Mexican American population presenting in labor: a cost-effectiveness analysis. Am J Obstet Gynecol. 2005;193(pt 2):1280—5.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ecker JL The cost-effectiveness of human immunodeficiency virus screening in pregnancy. Am J Obstet Gynecol. 1996;174:716—21.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Eisenstaedt RS, Getzen TE Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis. Am J Public Health. 1988;78:450—4.[Abstract/Free Full Text]
- Gorsky RD, Farnham PG, Straus WL, et al. Preventing perinatal transmission of HIV: costs and effectiveness of a recommended intervention. Public Health Rep. 1996;111:335—41.[Web of Science][Medline]
[Order article via Infotrieve]
- Grobman WA, Garcia PM The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol. 1999;181(pt 1):1062—71.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Halpern MT, Read JS, Ganoczy DA, Harris DR Cost-effectiveness of Cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS. 2000;14:691—700.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Harris ZK Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program. Health Econ. 2006; 15:147—58.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Heumann KS, Marx R., Lawrence SJ, et al. Cost-effectiveness of prevention referrals for high-risk HIV-negatives in San Francisco. AIDS Care. 2001;13:637—42.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Holtgrave DR, Kelly JA Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health. 1996;86:1442—5.[Abstract/Free Full Text]
- Holtgrave DR, Pinkerton SD, Jones TS, Lurie P., Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(suppl 1):S133—8.[Medline]
[Order article via Infotrieve]
- Holtgrave DR Estimating the effectiveness and efficiency of US HIV prevention efforts using scenario and cost-effectiveness analysis. AIDS. 2002;16:2347—9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Immergluck LC, Cull WL, Schwartz A., Elstein AS Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics. 2000;105:E54.[CrossRef][Medline]
[Order article via Infotrieve]
- Jackson BR, Busch MP, Stramer SL, AuBuchon JP The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721—9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Johnson-Masotti AP, Pinkerton SD, Kelly JA, Stevenson LY Cost-effectiveness of an HIV risk reduction intervention for adults with severe mental illness. AIDS Care. 2000;12:321—32.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Johnson-Masotti AP, Pinkerton SD, Sikkema KJ, Kelly JA, Wagstaff DA Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments. J Prim Prev. 2005;26:345—62.[CrossRef][Medline]
[Order article via Infotrieve]
- Kahn JG, Kegeles SM, Hays R., Beltzer N. Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men. J Acquir Immune Defic Syndr. 2001;27:482—91.[Web of Science][Medline]
[Order article via Infotrieve]
- Laufer FN Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir Immune Defic Syndr. 2001;28:273—8.[Web of Science][Medline]
[Order article via Infotrieve]
- Lee MB, Leibowitz A., Rotheram-Borus MJ Cost-effectiveness of a behavioral intervention for seropositive youth. AIDS Educ Prev. 2005;17:105—18.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lurie P., Avins AL, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994;272:1832—8.[Abstract/Free Full Text]
- Marin MG, Van Lieu J., Yee A., Bonner E., Glied S. Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers. J Occup Environ Med. 1999;41:754—60.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004;86:28—40.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mauskopf JA, Paul JE, Wichman DS, White AD, Tilson HH Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine: implications for HIV screening. JAMA. 1996;276:132—8.[Abstract/Free Full Text]
- Mrus JM, Goldie SJ, Weinstein MC, Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS. 2000;14:2543—52.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mrus JM, Tsevat J. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care. Med Decis Making. 2004;24:30—9.[Abstract/Free Full Text]
- Myers ER, Thompson JW, Simpson K. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998;91:174—81.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Owens DK, Harris RA, Scott PM, Nease RF Jr. Screening surgeons for HIV infection: a cost-effectiveness analysis. Ann Intern Med. 1995;122:641—52.[Abstract/Free Full Text]
- Owens DK, Nease RF Jr, Harris RA Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156: 394—404.[Abstract/Free Full Text]
- Payne MA, Lamb EJ Use of frozen semen to avoid human immunodeficiency virus type 1 transmission by donor insemination: a cost-effectiveness analysis. Fertil Steril. 2004;81:80—92.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479—87.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Phillips KA, Lowe RA, Kahn JG, Lurie P., Avins AL, Ciccarone D. The cost-effectiveness of HIV testing of physicians and dentists in the United States. JAMA. 1994;271:851—8.[Abstract/Free Full Text]
- Pinkerton SD, Holtgrave DR, Valdiserri RO Cost-effectiveness of HIV-prevention skills training for men who have sex with men. AIDS. 1997;11:347—57.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pinkerton SD, Holtgrave DR, Pinkerton HJ Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med. 1997;157:1972—80.[Abstract/Free Full Text]
- Pinkerton SD, Holtgrave DR, Bloom FR Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS. 1998;12:1067—78.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pinkerton SD, Holtgrave DR, DiFranceisco WJ, Stevenson LY, Kelly JA Cost-effectiveness of a community-level HIV risk reduction intervention. Am J Public Health. 1998;88:1239—42.[Abstract/Free Full Text]
- Pinkerton SD, Holtgrave DR, DiFranceisco W., Semaan S., Coyle SL, Johnson-Masotti AP Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions. AIDS. 2000;14:1257—68.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pinkerton SD, Holtgrave DR, Jemmott JB III. Economic evaluation of HIV risk reduction intervention in African-American male adolescents. J Acquir Immune Defic Syndr. 2000;25:164—72.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pinkerton SD, Holtgrave DR, Layde PM Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States. Prev Med. 2000;30:64—9. 54. Pinkerton SD, Johnson-Masotti AP, Otto-Salaj LL, Stevenson LY, Hoffmann RG Cost-effectiveness of an HIV prevention intervention for mentally ill adults. Ment Health Serv Res. 2001;3:45—55.[CrossRef][Medline]
[Order article via Infotrieve]
- Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004;18:2065—73.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med. 2004;164:46—54.[Abstract/Free Full Text]
- Ramsey SD, Nettleman MD Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers. Med Decis Making. 1992;12:142—8.[Abstract/Free Full Text]
- Resch S., Altice FL, Paltiel AD Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr. 2005;38:163—73.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Richter A., Loomis B. Health and economic impacts of an HIV intervention in out of treatment substance abusers: evidence from a dynamic model. Health Care Manag Sci. 2005;8:67—79.[CrossRef][Medline]
[Order article via Infotrieve]
- Sansom SL, Jamieson DJ, Farnham PG, Bulterys M., Fowler MG Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol. 2003;102:782—90.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Scheid DC, Hamm RM, Stevens KW Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers. Pharmacoeconomics. 2000;18:355—68.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sell RL, Jovell AJ, Siegel JE, et al. HIV screening of surgeons and dentists: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 1994;15:635—45.[Web of Science][Medline]
[Order article via Infotrieve]
- Stringer JS, Rouse DJ Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Obstet Gynecol. 1999;94:34—40.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sweat M., O'Donnell C., O'Donnell L. Cost-effectiveness of a brief video-based HIV intervention for African American and Latino sexually transmitted disease clinic clients. AIDS. 2001;15:781—7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tao G., Remafedi G. Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:83—90.[Web of Science][Medline]
[Order article via Infotrieve]
- Tuli K., Sansom S., Purcell DW, et al. Economic evaluation of an HIV prevention intervention for seropositive injection drug users. J Public Health Manag Pract. 2005;11:508—15.[Web of Science][Medline]
[Order article via Infotrieve]
- Varghese B., Peterman TA, Holtgrave DR Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS. 1999;13:1745—51.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Varghese B., Peterman TA Cost-effectiveness of HIV counseling and testing in US prisons. J Urban Health. 2001;78:304—12.[Web of Science][Medline]
[Order article via Infotrieve]
- Wang LY, Davis M., Robin L., Collins J., Coyle K., Baumler E. Economic evaluation of Safer Choices: a school-based human immunodeficiency virus, other sexually transmitted diseases, and pregnancy prevention program. Arch Pediatr Adolesc Med. 2000; 154:1017—24.[Abstract/Free Full Text]
- Zaric GS, Barnett PG, Brandeau ML HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90:1100—11.[Abstract/Free Full Text]
- Zaric GS, Bayoumi AM, Brandeau ML, Owens DK The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr. 2000;25:403—16.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bayoumi AM, Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. AIDS. 1998;12:1503—12.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bennett CL, Golub RM, Stinson TJ, et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:460—5.[Web of Science][Medline]
[Order article via Infotrieve]
- Bini EJ, Cohen J. Diagnostic yield and cost-effectiveness of endoscopy in chronic human immunodeficiency virus-related diarrhea. Gastrointest Endosc. 1998;48:354—61.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Caro JJ, O'Brien JA, Migliaccio-Walle K., Raggio G. Economic analysis of initial HIV treatment: efavirenz- versus indinavircontaining triple therapy. Pharmacoeconomics. 2001;19:95—104.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Castellano AR, Nettleman MD Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA. 1991; 266:820—4.[Abstract/Free Full Text]
- Cook J., Dasbach E., Coplan P., et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses. 1999;15:499—508.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Freedberg KA, Tosteson AN, Cohen CJ, Cotton DJ Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991;4:521—31.[Web of Science][Medline]
[Order article via Infotrieve]
- Freedberg KA, Hardy WD, Holzman RS, Tosteson AN, Craven DE Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making. 1996;16:29—35.[Abstract/Free Full Text]
- Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130—6.[Abstract/Free Full Text]
- Freedberg KA, Losina E., Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824—31.[Abstract/Free Full Text]
- Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med. 1999;130:97—107.[Abstract/Free Full Text]
- Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822—9.[Abstract/Free Full Text]
- Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001;111:140—9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Goldie SJ, Kaplan JE, Losina E., et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162:921—8.[Abstract/Free Full Text]
- Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632—41.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kimmel AD, Goldie SJ, Walensky RP, et al. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005;10:41—52.[Web of Science][Medline]
[Order article via Infotrieve]
- Kuehne FC, Bethe U., Freedberg K., Goldie SJ Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162:2545—56.[Abstract/Free Full Text]
- Mauskopf J., Lacey L., Kempel A., Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998;4:1004—12.[Web of Science][Medline]
[Order article via Infotrieve]
- Mauskopf J., Kitahata M., Kauf T., Richter A., Tolson J. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr. 2005;39:562—9.[Web of Science][Medline]
[Order article via Infotrieve]
- McCarthy BD, Wong JB, Munoz A., Sonnenberg FA Who should be screened for HIV infection? A cost-effectiveness analysis. Arch Intern Med. 1993;153:1107—16.[Abstract/Free Full Text]
- Moore RD, Chaisson RE Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:15—21.[Web of Science][Medline]
[Order article via Infotrieve]
- Mrus JM, Yi MS, Eckman MH, Tsevat J. The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants. Med Decis Making. 2002; 22(suppl):S38—44.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Oddone EZ, Cowper P., Hamilton JD, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ. 1993;307:1322—5.[Abstract/Free Full Text]
- Paltiel AD, Scharfstein JA, Seage GR III, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998;18(suppl):S93—105.[Abstract/Free Full Text]
- Paltiel AD, Goldie SJ, Losina E., et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32:783—93.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med. 2005;352:586—95.[Abstract/Free Full Text]
- Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS. 2000;14:2159—69.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rose DN, Sacks HS Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS. 1997;11:883—7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rose DN Short-course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effectiveness analysis. Ann Intern Med. 1998;129:779—86.[Abstract/Free Full Text]
- Sanders GD, Bayoumi AM, Sundaram V., et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570—85.[Abstract/Free Full Text]
- Sax PE, Islam R., Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41:1316—23.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sax PE, Losina E., Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39:69—77.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Schackman BR, Goldie SJ, Weinstein MC, Losina E., Zhang H., Freedberg KA Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001;91:1456—63.[Abstract/Free Full Text]
- Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002;162:2478—86.[Abstract/Free Full Text]
- Schackman BR, Oneda K., Goldie SJ The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. AIDS. 2004;18:1827—34.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Scharfstein JA, Paltiel AD, Freedberg KA The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making. 1997;17:373—81.[Abstract/Free Full Text]
- Scharfstein JA, Paltiel AD, Weinstein MC, et al. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Int J Technol Assess Health Care. 1999;15:531—47.[Web of Science][Medline]
[Order article via Infotrieve]
- Schulman KA, Lynn LA, Glick HA, Eisenberg JM Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991;114:798—802.[Abstract/Free Full Text]
- Shevitz AH, Wilson IB, McDermott AY, et al. A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting. J Acquir Immune Defic Syndr. 2005;38:399—406.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Simpson KN, Luo MP, Chumney E., Sun E., Brun S., Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5:294—304.[CrossRef]
- Sullivan SD, Mozaffari E., Johnson ES, Wolitz R., Follansbee SE An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther. 1996;18:546—58.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Walensky RP, Paltiel AD, Goldie SJ, et al. A therapeutic HIV vaccine: how good is good enough? Vaccine. 2004;22:4044—53.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Walensky RP, Weinstein MC, Kimmel AD, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118:292—300.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Weinstein MC, Goldie SJ, Losina E., et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440—50.[Abstract/Free Full Text]
- Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32—44.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Holtgrave DR, Pinkerton SD Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54—62.[Web of Science][Medline]
[Order article via Infotrieve]
- Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care. 1989;27(suppl):S233—53.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Duggan M., Evans W. Estimating the impact of medical innovation: the case of HIV antiretroviral treatments. NBER Working Paper 11109. Available at: http://papers.nber.org/papers/w11109. Accessed February 2005.
- Claxton K., Sculpher M., Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet. 2002;360:711—5.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gafni A., Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics. 2003;21:149—57.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Garber AM, Phelps CE Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1—31.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- George B., Harris A., Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001;19:1103—9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lim SS, Vos T., Peeters A., Liew D., McNeil JJ Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust. 2001;175:459—64.[Web of Science][Medline]
[Order article via Infotrieve]
- Ubel PA, Hirth RA, Chernew ME, Fendrick AM What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637—41.[Free Full Text]
- Zarkin GA, Lindrooth RC, Demiralp B., Wechsberg W. The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV. Health Serv Res. 2001;36:335—55.[Web of Science][Medline]
[Order article via Infotrieve]
- Johanson JF, Sonnenberg A. Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS): a medical decision analysis. Ann Intern Med. 1990;112:942—8.[Abstract/Free Full Text]
- Pinkerton SD, Holtgrave DR How HIV treatment advances affect the cost-effectiveness of prevention. Med Decis Making. 2000;20:89—94.[Abstract/Free Full Text]
Medical Decision Making, Vol. 27, No. 6,
789-821 (2007)
DOI: 10.1177/0272989X07306112

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|